Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
John R Adair, Philip W Howard, John A Hartley, David G Williams & Kerry A Chester. (2012) Antibody–drug conjugates – a perfect synergy. Expert Opinion on Biological Therapy 12:9, pages 1191-1206.
Read now
Read now
Lorenzo Galluzzi, Erika Vacchelli, Wolf Hervé Fridman, Jerome Galon, Catherine Sautès-Fridman, Eric Tartour, Jessica Zucman-Rossi, Laurence Zitvogel & Guido Kroemer. (2012) Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology 1:1, pages 28-37.
Read now
Read now
Articles from other publishers (25)
Hoda E. Mohamed, Medhat A. Al-Ghobashy, Samah S. Abbas & Shereen A. Boltia. (2023) Stability assessment of Polatuzumab vedotin and Brentuximab vedotin using different analytical techniques. Journal of Pharmaceutical and Biomedical Analysis 228, pages 115249.
Crossref
Crossref
Ashok K. Shakya & Rajashri R. Naik. (2022) The Chemotherapeutic Potentials of Compounds Isolated from the Plant, Marine, Fungus, and Microorganism: Their Mechanism of Action and Prospects. Journal of Tropical Medicine 2022, pages 1-17.
Crossref
Crossref
Ali Khader, Rozan Bokhari, Reza Hakimelahi, Christopher Scheirey, Jalil Afnan, Marta Braschi-Amirfarzan & Richard Thomas. (2022) A radiologist’s guide to novel anticancer therapies in the era of precision medicine. European Journal of Radiology Open 9, pages 100406.
Crossref
Crossref
Clement Chung. (2019) Current targeted therapies in lymphomas. American Journal of Health-System Pharmacy 76:22, pages 1825-1834.
Crossref
Crossref
Alejandro Carazo, Přemysl Mladěnka & Petr Pávek. (2019) Marine Ligands of the Pregnane X Receptor (PXR): An Overview. Marine Drugs 17:10, pages 554.
Crossref
Crossref
Malgorzata Bobrowicz, Radoslaw Zagozdzon, Joanna Domagala, Roberta Vasconcelos-Berg, Emmanuella Guenova & Magdalena Winiarska. (2019) Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives. Cancers 11:10, pages 1420.
Crossref
Crossref
Manisha Nigam, Hafiz Ansar Rasul Suleria, Mohammad Hosein Farzaei & Abhay Prakash Mishra. (2019) Marine anticancer drugs and their relevant targets: a treasure from the ocean. DARU Journal of Pharmaceutical Sciences 27:1, pages 491-515.
Crossref
Crossref
Cécile Chalouni & Sophia Doll. (2018) Fate of Antibody-Drug Conjugates in Cancer Cells. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Ricardo Calado, Miguel Costa Leal, Helena Gaspar, Susana Santos, António Marques, Maria Leonor Nunes & Helena Vieira. 2018. Grand Challenges in Marine Biotechnology. Grand Challenges in Marine Biotechnology
317
403
.
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Ulrike Lindequist. (2016) Marine-Derived Pharmaceuticals - Challenges and Opportunities. Biomolecules & Therapeutics 24:6, pages 561-571.
Crossref
Crossref
David J. Newman & Gordon M. Cragg. (2016) Natural Products as Sources of New Drugs from 1981 to 2014. Journal of Natural Products 79:3, pages 629-661.
Crossref
Crossref
Ryoji Kobayashi, Shosuke Sunami, Tetsuo Mitsui, Atsuko Nakazawa, Yuhki Koga, Takeshi Mori, Fumiko Tanaka, Jun-ichi Ueyama, Tomoo Osumi, Reiji Fukano, Kentaro Ohki, Masahiro Sekimizu & Tetsuya Mori. (2015) Treatment of pediatric lymphoma in Japan: Current status and plans for the future. Pediatrics International 57:4, pages 523-534.
Crossref
Crossref
LeeRon Shefet-Carasso & Itai Benhar. (2015) Antibody-targeted drugs and drug resistance—Challenges and solutions. Drug Resistance Updates 18, pages 36-46.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
595
653
.
Mariano Provencio, Antonio Sánchez & Margarita Sánchez-Beato. (2014) New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treatment Reviews 40:3, pages 457-464.
Crossref
Crossref
David Newman & Gordon Cragg. (2014) Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Marine Drugs 12:1, pages 255-278.
Crossref
Crossref
Antonio Gualberto. 2015. Molecular Oncology. Molecular Oncology
854
860
.
Mai Yoshikawa, Yohei Mukai, Yoshiaki Okada, Yuki Tsumori, Shin-ichi Tsunoda, Yasuo Tsutsumi, William C. Aird, Yasuo Yoshioka, Naoki Okada, Takefumi Doi & Shinsaku Nakagawa. (2013) Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood 121:14, pages 2804-2813.
Crossref
Crossref
Amy Grimsley, Katherine S. Shah & Trevor McKibbin. 2013. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
337
359
.
Jonathan R. Fromm, Julie A. McEarchern, Dana Kennedy, Anju Thomas, Andrei R. Shustov & Ajay K. Gopal. (2012) Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms. Clinical Lymphoma Myeloma and Leukemia 12:4, pages 280-283.
Crossref
Crossref
Bettina Bisig, Philippe Gaulard & Laurence de Leval. (2012) New biomarkers in T-cell lymphomas. Best Practice & Research Clinical Haematology 25:1, pages 13-28.
Crossref
Crossref
Deron R. Herr. 2012. International Review of Cell and Molecular Biology Volume 297. International Review of Cell and Molecular Biology Volume 297
45
81
.
Gregory Landes & Kathleen Elias. 2012. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics
183
240
.
Bérengère Vire, Alexandre David & Adrian Wiestner. (2011) TOSO, the Fcμ Receptor, Is Highly Expressed on Chronic Lymphocytic Leukemia B Cells, Internalizes upon IgM Binding, Shuttles to the Lysosome, and Is Downregulated in Response to TLR Activation. The Journal of Immunology 187:8, pages 4040-4050.
Crossref
Crossref